 To assess a quantitative kinetic model of FDG uptake measurement using PET in patients with aggressive Non-Hodgkins lymphoma and cancer of the pancreas, malignancies with known variability in disease aggressiveness and prognosis, for optimized tailoring of the therapeutic strategy in the individual patient. 